A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.
Lymphoma, Including Chronic Lymphocytic Leukemia|Solid Tumors
DRUG: navitoclax|DRUG: Rifampin
To determine the effect of rifampin on the pharmacokinetics of navitoclax., Weekly
To determine the safety of navitoclax when administered alone and in combination with rifampin in these patients., Daily
This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.